# Vivet Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vivet-therapeutics

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.vivet-therapeutics.com
- Total disclosed funding: $29M
- Latest round: Series A (Apr 1, 2017)
- Investors on record: 7

## About

Founded in 2016 and based in Paris, France, Vivet Therapeutics SAS operates as a developer of gene therapy treatments for orphan diseases. The company was founded by its CEO, Jean-Philippe Combal, and CSO, Gloria Gonzalez-Aseguinolaza. In February 2024, Vivet Therapeutics raised EUR 4.9 million in grant funding from France 2030.

Vivet Therapeutics develops gene therapies and orphan drugs for rare inherited metabolic disorders. The firm’s gene therapy product, VTX-806, is an (adeno-associated virus) AAV-based gene therapy for cerebrotendinous xanthomatosis (CTX). 

The company plans to use the funds raised in February 2024 to support the development of its gene therapy product called VTX-806.

## Funding rounds

- Series A, Apr 1, 2017, $29M — HealthCap, Novartis Venture Fund, Eurazeo, Ysios Capital Partners, Kurma Partners, Columbus Venture Capital, Roche Finance Ltd.

## Investors

- HealthCap — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series A
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A
- Columbus Venture Capital — Series A
- Roche Finance Ltd. — Series A